Abstract
Dysfunctioning of corticotropin-releasing factor (CRF) and its receptors (CRF1 and CRF2) has been linked to the development of stress-related disorders, such as affective disorders and drug abuse. The molecular characterization of CRF1 and CRF2 receptors and their splice variants has generated detailed information on their pharmacology, tissue distribution and physiology. In addition, the recent development of a small molecule CRF1 antagonist has provided important information on the contribution of this receptor to the development of stress-related diseases. Despite the high homology to the CRF1 receptor and the generation of peptide-based research tools, the physiological role of the CRF2 receptor is largely unclear. This is due to different expression patterns in rodents and primates and the lack of brainpenetrant CRF2-selective small molecule antagonists. However, the CRF2 receptor may be important for motivational types of behavior essential for survival, such as feeding and defense and impacts on cardiovascular function.
Keywords: stress-related disorders, drug abuse, depression, anxiety, CRF2, CRF1
CNS & Neurological Disorders - Drug Targets
Title: Corticotropin-Releasing Factor Receptor Antagonists in Affective Disorders and Drug Dependence - An Update
Volume: 5 Issue: 2
Author(s): Frank M. Dautzenberg and Thomas Steckler
Affiliation:
Keywords: stress-related disorders, drug abuse, depression, anxiety, CRF2, CRF1
Abstract: Dysfunctioning of corticotropin-releasing factor (CRF) and its receptors (CRF1 and CRF2) has been linked to the development of stress-related disorders, such as affective disorders and drug abuse. The molecular characterization of CRF1 and CRF2 receptors and their splice variants has generated detailed information on their pharmacology, tissue distribution and physiology. In addition, the recent development of a small molecule CRF1 antagonist has provided important information on the contribution of this receptor to the development of stress-related diseases. Despite the high homology to the CRF1 receptor and the generation of peptide-based research tools, the physiological role of the CRF2 receptor is largely unclear. This is due to different expression patterns in rodents and primates and the lack of brainpenetrant CRF2-selective small molecule antagonists. However, the CRF2 receptor may be important for motivational types of behavior essential for survival, such as feeding and defense and impacts on cardiovascular function.
Export Options
About this article
Cite this article as:
Dautzenberg M. Frank and Steckler Thomas, Corticotropin-Releasing Factor Receptor Antagonists in Affective Disorders and Drug Dependence - An Update, CNS & Neurological Disorders - Drug Targets 2006; 5 (2) . https://dx.doi.org/10.2174/187152706776359619
DOI https://dx.doi.org/10.2174/187152706776359619 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Endotoxin Agents. 3. Rapid Identification of High-Affinity Lipopolysaccharide-Binding Compounds in a Substituted Polyamine Library
Combinatorial Chemistry & High Throughput Screening Extraction, Processing, and Stabilization of Health-Promoting Fish Oils
Recent Patents on Food, Nutrition & Agriculture Mood Disorders in Elderly Population: Neurostimulative Treatment Possibilities
Recent Patents on CNS Drug Discovery (Discontinued) Renin-Angiotensin-Aldosterone System in Autosomal Dominant Polycystic Kidney Disease
Current Hypertension Reviews Anabolic Androgenic Steroids Abuse and Liver Toxicity
Mini-Reviews in Medicinal Chemistry Drugs and Aggression
Recent Patents on CNS Drug Discovery (Discontinued) Patents of Pentoxifylline Administration on Some Diseases and Chronic Wounds
Recent Patents on Regenerative Medicine Acute Decompensated Heart Failure Update
Current Cardiology Reviews Therapeutic Agents for COVID-19: an Overview
Current Drug Therapy Localisation of Endothelin-1 and its Receptors in Vascular Tissue as Seen at the Electron Microscopic Level
Current Vascular Pharmacology Stressing Conditions as Tools to Boost the Biosynthesis of Valuable Plant Natural Products
Recent Patents on Biotechnology Heat Shock Protein Inhibitors for the Treatment of Fungal Infections
Recent Patents on Anti-Infective Drug Discovery Tityus serrulatus Scorpion Venom and Toxins: An Overview
Protein & Peptide Letters Carotid Artery Stenting for the Prevention of Thromboembolic Stroke
Vascular Disease Prevention (Discontinued) Therapeutic Enhancement of IL-2 Through Molecular Design
Current Pharmaceutical Design Methylenedioxy- and Ethylenedioxy-Fused Indolocarbazoles: Potent Human Topoisomerase I Inhibitors and Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Aripiprazole: An FDA Approved Bioactive Compound to Treat Schizophrenia- A Mini Review
Current Drug Discovery Technologies Diagnostic use of Adenosine for Atrial Flutter with Regular Tachycardia
New Emirates Medical Journal Functional Roles of Benzothiazole Motif in Antiepileptic Drug Research
Mini-Reviews in Medicinal Chemistry Recent Advances and Future Perspectives of Triazole Analogs as Promising Antiviral Agents
Mini-Reviews in Medicinal Chemistry